USE OF URISAN IN PATIENTS WITH GOUT

Abstract

Objective: to evaluate the safety, tolerance, and efficacy of the herbal complex Urisan used in patients with gout within the Russian multicenter study. Subjects and methods. Thirty males aged 34 to 56 years with a valid diagnosis of gout after S.L. Wallace and a 1-7-year (mean 4,8 years) history of the disease were examined at the Rheumatology Unit of a Kursk regional hospital. Nineteen and 11 patients were stated to have tophaceous and nontophaceous gout, respectively. The total number of involved joints ranged from 3 to 10 (mean 4,6 joints). The study included patients with interictal gout. All the patients took Urisan in a full dose of 2 capsules (550 mg) twice daily for a month. Results. Prior to Urisan therapy, the mean serum level of uric acid (UA) was 569,5±102,4 ⎧mol/l; daily UA excretion averaged 4769,8 ⎧mol/l. Urisan therapy reduced UA levels by an average of 120 ⎧mol/l and increased daily urinary UA excretion by an average of 198,8 цmol/l. Conclusion. Urisan used against gout for 30 days causes an average 21% reduction in the serum levels of UA and a 4,1% increase in its urinary excretion. There were no exacerbations of gout during Urisan therapy.